Stock Traders Purchase Large Volume of Call Options on X4 Pharmaceuticals (NASDAQ:XFOR)

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) saw unusually large options trading activity on Tuesday. Traders acquired 9,665 call options on the company. This represents an increase of 3,751% compared to the average daily volume of 251 call options.

Insider Buying and Selling

In related news, COO Mary Dibiase sold 67,695 shares of the firm’s stock in a transaction on Monday, October 7th. The stock was sold at an average price of $0.57, for a total value of $38,586.15. Following the completion of the sale, the chief operating officer now owns 452,060 shares of the company’s stock, valued at $257,674.20. This trade represents a 13.02 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Adam S. Mostafa sold 230,645 shares of X4 Pharmaceuticals stock in a transaction on Monday, October 7th. The shares were sold at an average price of $0.55, for a total transaction of $126,854.75. The disclosure for this sale can be found here. Insiders have sold 580,800 shares of company stock valued at $321,447 over the last ninety days. 1.62% of the stock is owned by insiders.

Institutional Investors Weigh In On X4 Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in the stock. GSA Capital Partners LLP purchased a new position in shares of X4 Pharmaceuticals in the 3rd quarter worth about $340,000. K2 Principal Fund L.P. bought a new stake in X4 Pharmaceuticals during the 2nd quarter valued at about $284,000. AQR Capital Management LLC raised its holdings in X4 Pharmaceuticals by 1,080.3% in the second quarter. AQR Capital Management LLC now owns 424,042 shares of the company’s stock worth $246,000 after buying an additional 388,115 shares during the last quarter. State Street Corp lifted its stake in shares of X4 Pharmaceuticals by 6.8% in the third quarter. State Street Corp now owns 2,952,895 shares of the company’s stock worth $1,976,000 after buying an additional 189,105 shares in the last quarter. Finally, Barclays PLC grew its holdings in shares of X4 Pharmaceuticals by 196.0% during the third quarter. Barclays PLC now owns 277,682 shares of the company’s stock valued at $185,000 after buying an additional 183,861 shares during the last quarter. 72.03% of the stock is owned by institutional investors.

X4 Pharmaceuticals Stock Performance

Shares of XFOR opened at $0.67 on Wednesday. The company has a quick ratio of 4.80, a current ratio of 4.89 and a debt-to-equity ratio of 1.26. The stock has a market cap of $114.85 million, a P/E ratio of -7.48 and a beta of 0.35. The business’s 50 day moving average price is $0.48 and its 200-day moving average price is $0.67. X4 Pharmaceuticals has a 52 week low of $0.26 and a 52 week high of $1.60.

Analysts Set New Price Targets

A number of research analysts have recently commented on the company. HC Wainwright lowered their target price on X4 Pharmaceuticals from $5.00 to $1.50 and set a “buy” rating for the company in a research note on Thursday, November 14th. Stifel Nicolaus lowered their price objective on X4 Pharmaceuticals from $5.00 to $4.00 and set a “buy” rating for the company in a research report on Thursday, November 14th.

X4 Pharmaceuticals Company Profile

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.